Sanofi-aventis Acquires TargeGen to Strengthen its Oncology Pipeline
By Staff Editor
Pharma Deals Review: Vol 2010 Issue 7 (Table of Contents)
Published: 2 Sep-2010
DOI: 10.3833/pdr.v2010.i7.1361 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Sanofi-aventis is acquiring TargeGen, a developer of small molecule kinase inhibitors for the treatment of various types of cancers, in a deal potentially valued at US$560 M...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS